Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.
La Verde N, Riva A, Cona MS, Gabrieli A, Cattaneo M, Fasola C, Lipari G, De Stradis C, Favorito V, Lombardi Stocchetti B, Chizzoniti D, Covizzi A, Rulli E, Galli F, Ruggieri L, Gambaro A, Ferrario S, Dalu D, Tarkowski MS. La Verde N, et al. Among authors: favorito v. Int J Cancer. 2023 Feb 15;152(4):661-671. doi: 10.1002/ijc.34273. Epub 2022 Sep 28. Int J Cancer. 2023. PMID: 36056571 Free PMC article.
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.
Favorito V, Ricciotti I, De Giglio A, Fabbri L, Seminerio R, Di Federico A, Gariazzo E, Costabile S, Metro G. Favorito V, et al. Expert Opin Emerg Drugs. 2024 Apr 8:1-16. doi: 10.1080/14728214.2024.2331139. Online ahead of print. Expert Opin Emerg Drugs. 2024. PMID: 38572595 Review.
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, De Giglio A, Pecci F, Lamberti G, Ambrogio C, Ricciuti B. Di Federico A, et al. Among authors: favorito v. Curr Oncol Rep. 2023 Sep;25(9):1017-1029. doi: 10.1007/s11912-023-01436-y. Epub 2023 Jun 28. Curr Oncol Rep. 2023. PMID: 37378881 Review.